The trial also documented a reduction in WOMAC pain scores by up to 75.8%, improvements in non-HDL cholesterol, and reductions in systolic blood pressure
However, EASL seemingly broke its own embargo, as Zealand said in its statement about the disclosure of the metabolic dysfunction-associated steatohepatitis (MASH) data
[1] They screened 544 articles published between 1993 and 2024
On top of that, the patient must be on a documented diet and exercise plan and have already tried two other weight loss medications (phentermine, diethylpropion, phentermine/topiramate, naltrexone/bupropion)
Micronutrient adequacy (vitamin D status, magnesium, zinc, copper balance, vitamin C)
When constipation signals something more serious Most GLP-1 constipation is manageable